Abstract:The application of population approaches to drug development is recommended in several US Food and Drug Administration (Fl)A) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge. upon drug Safety and efficacy. This article briefly discusses the 2-stage approach to the estimation of population pharmacokinetic parameters, which requires serial multiple measurements on each participant, and comprehensively reviews the nonlinear mixed-effects. modelling approach, which can be applied in situations where extensive sampling is not done on all or any of the participants.Certain preliminary information, such as the compartment model used in describing the pharmacokinetics of the drug, is required for a population pharmacokinetic study. The practical design considerations of the location of sampling times, number of samples/participants and the need to sample an individual more than once should be borne in mind. Simulation may be useful for choosing the study design that will best meet study objectives.The objectives of the population pharmacokinetic study can be secondary to the objectives of the primary clinical study lin which case an add-on population pharmacokinetic protocol may be needed) or primary (when a stand-alone protocol is required). Having protocols for population pharmacokinetic studies is an integral part of 'good pharmacometric practice'.Real-time data assembly and analysis permit an ongoing evaluation of site compliance with the study protocol and provide the opportunity to correct violations of study procedures. Adequate policies and procedures should be in place for study blind maintenance. Real-time data assembly creates the opportunity for detecting and correcting errors in concentration-time data, drug administration history and covariate data.Population pharmacokinetic analyses may be undertaken in 3 interwoven steps: exploratory data analysis, model development and model validation (i.e. predictive performance). Documentation for regulatory purposes should include a complete inventory of key runs in the analyses undertaken (with flow diagrams if possible), accompanied by articulation of objectives, assumptions and hypotheses. Use of diagnostic analyses of goodness of fit as evidence of reliability of results is advised. Finally, the use of stability testing or model validation may be warranted to support label claims.The opinions expressed in this article were revised by incorporating comments from various sources and published by the FDA as 'Guidance for Industry: Population Pharmacokinetics' (see the FDA home page http://www.fda.gov for further information).

Simulation of a security function based on vehicle-to-X communication and automotive lighting

CPhaMAS: An Online Platform for Pharmacokinetic Data Analysis Based on Optimized Parameter Fitting Algorithm

Parameter grouping and co-estimation in physiologically based kinetic models using genetic algorithms

Reinforcement Learning Based Model Selection and Parameter Estimation for Pharmacokinetic Analysis in Drug Selection.

A fuzzy neartude based approach to simulate the two-compartment pharmacokinetic model

A Branch and Bound method for the exact parameter identification of the PK/PD model for anesthetic drugs

Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models

Accuracy and Performance of Functional Parameter Estimation Using a Novel Numerical Optimization Approach for GPU-Based Kinetic Compartmental Modeling

Density-based Monte Carlo filter and its applications in estimation of unobservable variables and pharmacokinetic parameters

Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring

The study of analysis technology of automotive exhaust

Population Pharmacokinetics - A Regulatory Perspective

Investigation of Fractional Compartmental Models with Application to Amiodarone Drug Diffusion in Pharmacokinetics

Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors

Estimating Organ-to-Plasma Ratios in physiologically based PK modeling: a simplified approach for early drug discovery

In Silico Prediction of Human Intravenous Pharmacokinetic Parameters with Improved Accuracy

A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization

A Systematic Approach for Estimating Colloidal Particle Adsorption Model Parameters

A SAEM Algorithm for Fused Lasso Penalized Non Linear Mixed Effect Models: Application to Group Comparison in Pharmacokinetic

ADME evaluation in drug discovery. 1. Applications of genetic algorithms to the prediction of blood-brain partitioning of a large set of drugs.

Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations